Goldman Sachs released a research report stating that WUXI XDC (02268) continues to demonstrate robust order momentum, supported by steady client demand, particularly from U.S. customers. The company remains active in exploring areas beyond ADC (antibody-drug conjugates), such as AOC (antibody-oligonucleotide conjugates) and RDC (radiopharmaceutical drug conjugates). Progress toward its full-year revenue growth target of 45% year-on-year remains on track. Additionally, the company is actively negotiating contracts for its Singapore facility with clients, expecting to finalize several agreements by year-end. However, due to the time required for capacity expansion, the facility's revenue contribution is expected to remain limited until 2027. Other capacity and workforce expansions are proceeding as planned, with recruitment efforts ongoing. Goldman Sachs maintains a target price of HK$63.3 for the stock.